Loading...

CAMP CAMP4 THERAPEUTICS CORP Management Changes 8-K Filing

CMP4

CMP

CAMP4 THERAPEUTICS CORP

(CAMP)

2026 8-K

New Data Release

Financial Results

Director Appointment

Financial Results Update

Corporate Update

Lease Agreement Update

Stock Offering Update

Collaboration Agreement

Financial Results Announced

Toxicology Studies Initiated

Securities Agreement

Financial Results Announcement

Product Expansion

Financial Statements

Financial Results

Board Appointments

Corporate Presentation

Financial Results

External Links:

On March 18, 2026, Camp4 Therapeutics Corp appointed Michael MacLean as a Class III director effective April 1, 2026. The board size increased to nine, and MacLean will receive stock options to purchase 56,000 shares under the 2024 Equity Incentive Plan.

AI Assistant

CAMP4 THERAPEUTICS CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.